The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
This type of tracking helps a practice understand how radiologists interact with AI, whether they're appropriately rejecting incorrect results, and if the technology is improving detection of important findings.
Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's FDA 510(k)-pending photon-counting CT scanner.
Intravascular lithotripsy is expected to see even wider adoption when lower-profile catheters are introduced and device costs start to drop, explained Samin Sharma, MD.
There is still a lack of lack of standardized treatment protocols for pulmonary embolism. This is mainly due to limited data and a lack of reliable risk assessments, one specialist explained.
New American College of Radiology CEO Dana Smetherman, MD, discusses the impact of reimbursement cuts, issues with staffing costs and prior authorization.
Most EP clinical study data are from men, Anne Kroman, DO, explained in an interview. This is a significant problem, she said, because heart rhythm issues look quite different in women.
Sahil Parikh, MD, director of endovascular services, New York-Presbyterian, explains details from the big-data REAL-PE study comparing mechanical thrombectomy to ultrasound assisted catheter thrombolysis.
Anne Kroman, DO, PhD, assistant professor at Medical University of South Carolina (MUSC), explains mentoring efforts for women in EP and why it is important for patients to see more female electrophysiologists to help overcome barriers.
Emily Lau, MD, a women's health expert with Massachusetts General Hospital, thinks major changes are needed in how we diagnose CVD in women. "Our guidelines need to be more precise and offer sex-specific recommendations," she says.
In rural Oklahoma, double amputees due to untreated peripheral artery disease face mortality rates around 35% after one year and 60% after two. Jim Melton, DO, hopes his mobile cardiology clinics can make a difference for these patients.
